Recombinant Thrombomodulin Domain 1 Promotes Diabetic Corneal Wound Healing by Inhibiting HMGB1 Production and NLRP3 Inflammasome
Mediators of Inflammation · 2026
DOI: 10.1155/mi/8089754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, 2026. Verfasst von Kuan-Ying Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Education Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ncku.edu.tw. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, HMGB1 Protein, Wound Healing, Thrombomodulin. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council.
Themen: Wundversorgung
Abstract (Originalsprache)
Purpose
To investigate the therapeutic potential of recombinant thrombomodulin domain 1 (rTMD1) in diabetic corneal wound healing and to elucidate its underlying mechanisms using in vitro and in vivo models. Methods rTMD1 was produced using the Pichia pastoris expression system and purified. Human corneal epithelial cells (HCECs) were cultured under normal glucose (NG) and high glucose (HG) conditions, with or without rTMD1 treatment. Wound healing rates were evaluated using a scratch assay. Diabetes was induced in C57BL/6 mice via streptozotocin (STZ) injections. Corneal wounds were created and treated with rTMD1 or PBS, and wound healing was assessed via fluorescein staining. Inflammatory markers, including HMGB1, TLR4, NLRP3, and IL‐1β, were analyzed via quantitative PCR (qPCR), Western blot, and immunofluorescence staining.
Results
In vitro, HCECs treated with rTMD1 under HG conditions demonstrated a higher wound healing rate compared to untreated cells ( p = 0.0049). In vivo, rTMD1 significantly enhanced corneal wound healing in diabetic mice, with faster wound closure compared to PBS‐treated controls at 24 h ( p = 0.005) and 48 h ( p < 0.0001). rTMD1 treatment reduced the expression of HMGB1, TLR4, NLRP3, and IL‐1β at both mRNA and protein levels, indicating suppression of inflammation.
Conclusions
Topical application of rTMD1 promotes corneal epithelial wound healing in diabetic conditions by inhibiting HMGB1/TLR4/NLRP3‐mediated inflammation. rTMD1 holds promise as a potential therapeutic agent for diabetic keratopathy, although further studies are needed to validate its clinical efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Education Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ncku.edu.tw.
- Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng-Li Rd., Tainan, 704, Taiwan, ncku.edu.tw.
- Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ncku.edu.tw.
- Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ncku.edu.tw.
- International Center for Wound Repair and Regeneration, National Cheng Kung University, Tainan, Taiwan, ncku.edu.tw.
ORCID-Profile: Kuan-Ying Chen, Cheng-Hsiang Kuo, Yi-Hsun Huang
Förderung
- National Science and Technology Council
Zitieren
APA
Chen, K. Y., Peng, I. C., Wu, H. L., Kuo, C. H., & Huang, Y. H. (2026). Recombinant Thrombomodulin Domain 1 Promotes Diabetic Corneal Wound Healing by Inhibiting HMGB1 Production and NLRP3 Inflammasome. Mediators of Inflammation. https://doi.org/10.1155/mi/8089754
Vancouver
Chen KY, Peng IC, Wu HL, Kuo CH, Huang YH. Recombinant Thrombomodulin Domain 1 Promotes Diabetic Corneal Wound Healing by Inhibiting HMGB1 Production and NLRP3 Inflammasome. Mediators of Inflammation. 2026. doi:10.1155/mi/8089754
BibTeX
@article{Chen2026,
author = {Chen, Kuan-Ying and Peng, I-Chen and Wu, Hua-Lin and Kuo, Cheng-Hsiang and Huang, Yi-Hsun},
title = {Recombinant Thrombomodulin Domain 1 Promotes Diabetic Corneal Wound Healing by Inhibiting HMGB1 Production and NLRP3 Inflammasome},
journal = {Mediators of Inflammation},
year = {2026},
doi = {10.1155/mi/8089754}
}
EUVIMED